Brevan Howard Capital Management
TRDA icon

Brevan Howard Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Brevan Howard Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$250K Buy
33,969
+7,620
+29% +$73.1K ﹤0.01% 1799
2026
Q1 		$333K Sell
26,349
-21,618
-45% -$248K ﹤0.01% 1555
2025
Q4 		$493K Buy
+47,967
New +$404K 0.01% 1116

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Brevan Howard Capital Management's TRDA Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Entrada Therapeutics (TRDA) stake by 29% in Q2 2026, buying an estimated $73.1K and bringing the position to 33,969 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #1799.

Brevan Howard Capital Management first reported a position in TRDA in Q4 2025 and has held it in 3 quarters since. The position peaked at $493K in Q4 2025. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Brevan Howard Capital Management held 33,969 shares of Entrada Therapeutics worth $250K as of Q2 2026.
  • Brevan Howard Capital Management bought 7,620 Entrada Therapeutics shares in Q2 2026, an estimated $73.1K.
  • Entrada Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1799 holding.
  • Brevan Howard Capital Management first reported a position in Entrada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's Entrada Therapeutics position peaked at $493K in Q4 2025.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.